James Croop, MD, PhD

James Croop, MD, PhD

Professor of Pediatrics

Phone: 317-944-8784
Email: jcroop@iu.edu
705 Riley Hospital Drive, ROC 4340 Indianapolis, IN 46202



Pediatric Hematology Oncology

Areas of Interest

Developing new and novel agents for treating children with cancer. 


Dr. James Croop is a Professor of Pediatrics at Indiana University in the Section of Pediatric Hematology and Oncology. He attended the University of Pennsylvania School of Medicine obtaining both MD and PhD degrees. He did his Pediatric residency at the Children’s Hospital of Philadelphia and his fellowship in Pediatric Hematology/Oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute. He was a visiting fellow at the Massachusetts's Institute of Technology Cancer Center. Dr. Croop's research included cloning and characterizing the multidrug resistance gene and developing tumor vaccine models in mice to treat leukemia. He has been the principal investigator of clinical gene therapy trials  with the MGMT DNA repair gene to protect hematopoietic precursors from the side effects of chemotherapy and the CGD gene to correct the molecular defect in patients with Chronic Granulomatous Disease. Dr. Croop is currently the institution principal investigator for the Children’s Oncology Group Phase I Program at Riley Children’s Hospital. Dr. Croop has served as the Research Subject Advocate for the GCRC and is currently the Chair of the Children's Oncology Group Institutional Performance Monitoring Committee. He has been the Chair of the Indiana University Simon Cancer Center Scientific Review Committee since 1999. 


1980 MD, PhD University of Pennsylvania
1983 Completed Residency Children's Hospital of Philadelphia
1986 Completed Fellowship Dana-Farber Cancer Institute and Children's Hospital Medical Center, Boston


Riley Outpatient Center
705 Riley Hospital Drive
Indianapolis, IN 46202
317-944-2143 phone
317-944-3107 fax

Research & Grants

Dr. Croop is the institutional principle investigator for the Children's Oncology Group Phase I Program and a number of pharmaceutical company sponsored trials.


P30 CA082709-12 (Loehrer, P.) 

Cancer Center Support Grant, NIH/NCI 

Co-Leader Clinical Research Office

Chair-Protocol Review and Monitoring

Goals: The major goal of this project is establish an NCI designated Cancer Center by facilitating cancer research, education, patient care, and cancer control and prevention to accomplish its mission of reducing the incidence, morbidity, and mortality of cancer.


U01 CA097452-11  

National Childhood Cancer Foundation 

Children’s Oncology Group (COG) Chair’s Grant 

Institutional Principal Investigator COG Phase I Program


Novartis Pharmaceutical

Institutional Principal Investigator

A Multi-Center, Open-Label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients with Imatinib Resistant/Intolerant Ph+ CML Chronic Phase (CP) or Accelerated Phase (AP) or with Refractory/Relapsed Ph+ ALL.


Dunussi-Joannopoulos, K., Dranoff, G.,Weinstein, H., Ferrara , J., Bierer, B. E., Croop, J.M. Gene Immunotherapy in murine Acute Myeloid Leukemia: Granulocyte-Macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compare with B7 family and other cytokine vaccines. Blood. 1998; 91:222-230.

Barbarics, E., Kronauge, J.F., Cohen, D., Davison, A., Jones, A.G. Croop, J.M. Characterization of P-glycoprotein transport and inhibition in vivo. 1998; Cancer Res 58:276-282.

Croop J.M., Cooper, R., Seshadri R., Fernandez, C., Graves, V., Kreissman, S., Smith, F.O., Cornetta, K., Williams, D.A., Abonour R. Large Scale Mobilization and Isolation of CD34+ Cells from Normal Donors. Bone Marrow Transplantation. 2000; 26:1271-1279.

Croop, J.M., Cooper, R., Fernandez, C., Graves, V., Kreissman S., Hanenberg, H., Smith, F.O., Cornetta K., Williams D.A. Mobilization and Collection of Peripheral Blood CD34+ Cells from Patients with Fanconi Anemia. Blood 2001; 98: 2917-2921

Kumar, M., Vik, T., Johnson, C. Southwood, M.E., Croop, J.M. Treatment, outcome and cost of care in children with idiopathic thrombocytopenic purpura. Am J Hem 2005; 78:181-187.

Cavalier M.E., Davis M.M., Croop J.M. Germline p53 mutation presenting as synchronous tumors. Journal of Pediatric Hematology/Oncology. 2005 27:441-443.

Daw N.C., Furman W.L., Stewart C.F., Iacono L.C., Krailo M., Bernstein M.L., Dancey J.E., Speights R.A., Blaney S.M., Croop J.M., Reaman G.H., Adamson P.C. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. Journal of Clinical Oncology. 2005 23:6172-6180.

Cornetta K. Croop J. Dropcho E. Abonour R. Kieran MW. Kreissman S. Reeves L. Erickson LC. Williams DA. A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase. Cancer Gene Therapy. 2006 13:886-895.

Mondick J.T., Johnson BM. Haberer L.J., Sale M.E., Adamson P.C., Coté C.J., Croop J.M.,. Russo M.W., Barrett J.S., Hoke J.F. Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months. European Journal of Clinical Pharmacology. 2010 66:77-86.

Creary S, Heiny M, Croop J, Fallon R, Vik T, Hulbert M, Knoderer H, Kumar M, Sharathkumar A. Clinical course of postthrombotic syndrome in children with history of venous thromboembolism. Blood Coagul Fibrinolysis. 2012 23:39-44.